KEAP1-NRF2途径作为EGFR突变非小细胞肺癌的新疗法标
Jae-Sun Choi1, Hye-Min Kang2, Kiyong Na3
1Clinical Research Institute, Kyung Hee University Medical Center, Seoul, Republic of Korea.
Tuberculosis and respiratory diseases
|September 23, 2024
概括
抑制NRF2通路增强了细胞死亡和瘤生长抑制在EGFR突变肺癌耐药的TKIs. NRF2调制提供了一个新的策略来对抗TKI抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 凯尔奇类ECH相关蛋白1 (KEAP1) -核因子红素-2-相关因子2 (NRF2) 途径调节细胞防御氧化和代谢压力.
- 这一途径与抗化疗和免疫疗法的耐药性有关,但其在瘤基因上瘤中的作用尚不清楚.
- 研究NRF2通路作为EGFR突变非小细胞肺癌 (NSCLC) 的治疗点的潜力.
研究的目的:
- 确定NRF2通路是否是EGFR突变NSCLC中可行的治疗点.
- 评估NRF2抑制对EGFR突变NSCLC模型中细胞死亡和瘤生长的影响.
主要方法:
- 评估基线NRF2表达在父母和耐基菲替尼的EGFR突变肺癌细胞中.
- 使用异种移植小鼠模型,利用NRF2抑制剂评估其对细胞死亡 in vitro和瘤生长 in vivo的影响.
- 进行RNA测序以分析NRF2抑制后的转录变化.
主要成果:
- 在EGFR突变细胞中观察到增强的NRF2表达,特别是在耐吉提尼布的细胞系中.
- 抑制NRF2导致NRF2水平的剂量依赖性下降,并诱导显著的细胞死亡.
- 结合NRF2抑制剂和奥西默蒂尼布的联合治疗改善了细胞死亡在体外,并抑制了瘤生长在体内.
- RNA测序确定了NRF2抑制后多个基因和信号通路的改变表达.
结论:
- 抑制NRF2有效增强细胞死亡,并抑制TKI耐药EGFR突变肺癌的瘤生长.
- 向NRF2通路是一个有希望的治疗策略,以克服NSCLC中EGFR-TKI的耐药性.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Enzyme-linked Receptors
77.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
